Nintedanib Eye Formulation for Glaucoma Surgery Scar Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Glaucoma filtration surgery is prone to high failure rates due to excessive postoperative wound healing with subsequent fibrosis and scar formation, leading to obstruction of drainage and loss of intraocular pressure control.
Innovation Solution
Administering nintedanib, a kinase inhibitor, in the form of topical ocular formulations or implants to inhibit vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and fibroblast growth factor receptor 2, thereby blocking key pathogenic factors involved in excess wound healing and scar formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glaucoma filtration surgery is performed to reduce intraocular pressure, then fluid drainage is improved, but scar formation and fibrosis occur at the surgical site
Solution Approach 1:
The patent applies preliminary action by administering nintedanib topically to the eye before or during glaucoma filtration surgery to prevent scar formation and fibrosis before they can develop. The drug is applied in the surgical solution or as a preoperative drop, proactively inhibiting pathological wound healing processes before they cause harm to the filtration site.
Solution Approach 2:
Nintedanib serves as an intermediary substance that mediates between the surgical trauma and the harmful fibrotic response. The drug inhibits receptor tyrosine kinases (VEGFR, PDGFR, FGFR) that are overactivated during wound healing, thereby blocking the signal transduction pathway that leads to excessive scar formation and fibrosis at the filtration site.
2Stability of the object's composition
If excessive wound healing occurs to close the surgical site, then wound closure is achieved, but filtration is obstructed and pressure control is lost
Solution Approach 1:
The patent applies local quality by selectively inhibiting wound healing at the filtration site where excessive scarring is harmful, while allowing normal wound healing to proceed in other areas of the eye. Nintedanib is topically applied to concentrate the drug locally at the surgical site, where it specifically targets and inhibits pathological fibrosis and scar formation that would obstruct filtration, without compromising overall wound closure integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the success of glaucoma surgery by extending the duration of reduced intraocular pressure, improving bleb survival, and reducing scar formation, thus increasing the success rate of glaucoma filtration surgery.
Implementation Method 1
nintedanib, a kinase inhibitor, in the form of topical ocular formulations or implants to inhibit vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and fibroblast growth factor receptor 2
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.